This protocol proposes to use high-dose yttrium-90 (90y) labeled to an antibreast ab (bre-3) with autologous stem cell support in a dose escalation pattern. The hypothesis of this approach is to try to reduce organ toxicity by targeting the treatment to the tumor and sparing the unwanted normal organ toxicity.
Showing the most recent 10 out of 1065 publications